These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20514850)

  • 1. Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
    Maha A; Cheong SK; Leong CF; Seow HF
    Malays J Pathol; 2009 Dec; 31(2):81-91. PubMed ID: 20514850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
    Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
    Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.
    Weldon CB; Parker AP; Patten D; Elliott S; Tang Y; Frigo DE; Dugan CM; Coakley EL; Butler NN; Clayton JL; Alam J; Curiel TJ; Beckman BS; Jaffe BM; Burow ME
    Int J Oncol; 2004 Jun; 24(6):1473-80. PubMed ID: 15138590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia.
    Yiau SK; Lee C; Mohd Tohit ER; Chang KM; Abdullah M
    J Recept Signal Transduct Res; 2019 Jun; 39(3):276-282. PubMed ID: 31509041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
    Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
    Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H
    Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
    Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
    Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.
    Huang TS; Myklebust LM; Kjarland E; Gjertsen BT; Pendino F; Bruserud Ø; Døskeland SO; Lillehaug JR
    Mol Cancer; 2007 Apr; 6():31. PubMed ID: 17451600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
    Heuser M; Wingen LU; Steinemann D; Cario G; von Neuhoff N; Tauscher M; Bullinger L; Krauter J; Heil G; Döhner H; Schlegelberger B; Ganser A
    Haematologica; 2005 Nov; 90(11):1484-92. PubMed ID: 16266895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between bcl-X(L) expression and sensitivity to chemotherapy in acute myeloid leukemic cells].
    Zhou J; Chen Y; Li C; Wang B; Wang B; Qiao Z; Zhou M; Findley HW; Wang B
    Zhonghua Xue Ye Xue Za Zhi; 1997 Nov; 18(11):584-7. PubMed ID: 15625897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
    Lemez P; Gáliková J; Haas T
    Neoplasma; 2000; 47(1):41-7. PubMed ID: 10870686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.